Clinical COPD phenotypes: a novel approach using principal component and cluster analyses

Classification of chronic obstructive pulmonary disease (COPD) is usually based on the severity of airflow limitation, which may not reflect phenotypic heterogeneity. Here, we sought to identify COPD phenotypes using multiple clinical variables. COPD subjects recruited in a French multicentre cohort were characterised using a standardised process. Principal component analysis (PCA) was performed using eight variables selected for their relevance to COPD: age, cumulative smoking, forced expiratory volume in 1 s (FEV1) (% predicted), body mass index, exacerbations, dyspnoea (modified Medical Research Council scale), health status (St George’s Respiratory Questionnaire) and depressive symptoms (hospital anxiety and depression scale). Patient classification was performed using cluster analysis based on PCA-transformed data. 322 COPD subjects were analysed: 77% were male; median (interquartile range) age was 65.0 (58.0–73.0) yrs; FEV1 was 48.9 (34.1–66.3)% pred; and 21, 135, 107 and 59 subjects were classified in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1, 2, 3 and 4, respectively. PCA showed that three independent components accounted for 61% of variance. PCA-based cluster analysis resulted in the classification of subjects into four clinical phenotypes that could not be identified using GOLD classification. Importantly, subjects with comparable airflow limitation (FEV1) belonged to different phenotypes and had marked differences in age, symptoms, comorbidities and predicted mortality. These analyses underscore the need for novel multidimensional COPD classification for improving patient care and quality of clinical trials.

[1]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[2]  D. Nagel,et al.  Cluster analysis in diagnosis. , 1992, Clinical chemistry.

[3]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[4]  P. O'Byrne,et al.  Is nedocromil sodium effective treatment for asthma? , 1993, The European respiratory journal.

[5]  J. Muir,et al.  Pulmonary rehabilitation in chronic respiratory insufficiency , 1993 .

[6]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[7]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[8]  R. Deyo,et al.  Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. , 1994, Thorax.

[9]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[10]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[11]  I. Guyon,et al.  Detecting stable clusters using principal component analysis. , 2003, Methods in molecular biology.

[12]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[13]  I. Pavord,et al.  Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  B. Celli,et al.  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[15]  R. Mitchell Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance , 2006 .

[16]  B. Nordestgaard,et al.  Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. , 2006, American journal of respiratory and critical care medicine.

[17]  B. Celli Chronic obstructive pulmonary disease phenotypes and their clinical relevance , 2006 .

[18]  B. Celli Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. , 2006, Proceedings of the American Thoracic Society.

[19]  A. Khodursky,et al.  Functional Genomics: Methods And Protocols , 2007 .

[20]  T. Ng,et al.  Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.

[21]  David M Kent,et al.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.

[22]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[23]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[24]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[25]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[26]  G. Turino COPD and biomarkers: the search goes on , 2008, Thorax.

[27]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[28]  S. Zakynthinos,et al.  Chest wall volume regulation during exercise in COPD patients with GOLD stages II to IV , 2008, European Respiratory Journal.

[29]  B. Celli,et al.  Predictors of Survival in COPD: more than just the FEV1. , 2008, Respiratory medicine.

[30]  G. Criner,et al.  National Emphysema Treatment Trial: the major outcomes of lung volume reduction surgery in severe emphysema. , 2008, Proceedings of the American Thoracic Society.

[31]  H. Magnussen,et al.  Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. , 2008, American journal of respiratory and critical care medicine.

[32]  M. Weatherall,et al.  Distinct clinical phenotypes of airways disease defined by cluster analysis , 2009, European Respiratory Journal.

[33]  Nicolas Roche,et al.  Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.

[34]  D. Donaire-Gonzalez,et al.  Physical activity and clinical and functional status in COPD. , 2009, Chest.